Migliorelli Andrea, Ciorba Andrea, Manuelli Marianna, Stomeo Francesco, Pelucchi Stefano, Bianchini Chiara
ENT & Audiology Unit, Department of Neurosciences, University Hospital of Ferrara, 44100 Ferrara, Italy.
Diagnostics (Basel). 2024 Nov 26;14(23):2662. doi: 10.3390/diagnostics14232662.
The aim of this review is to assess the utility of circulating HPV tumor DNA (ctHPVDNA) clearance in the monitoring of molecular residual disease in HPV-related oropharyngeal squamous cell carcinoma (OPSCC) patients. Recently, ctHPVDNA in patient plasma was found to be a promising biomarker for HPV OPSCC. Changes in this biomarker appear to be associated with treatment response and may be useful for identifying molecular residual disease. A review of the literature was performed using PubMed/MEDLINE, EMBASE, and Cochrane Library databases according to the PRISMA criteria for scoping reviews (from 2017 to July 2024). A total of 5 articles and 562 patients have been included. Three studies examine the role of ctHPVDNA clearance in CRT, while the remaining two studies consider surgery as a treatment option. The results of this scoping review indicate that ctHPVDNA has a potential role to serve as a valuable biomarker in the assessment of molecular residual disease. Further studies are required to confirm the efficacy of this marker for stratifying this group of patients.
本综述的目的是评估循环HPV肿瘤DNA（ctHPVDNA）清除在监测HPV相关口咽鳞状细胞癌（OPSCC）患者分子残留疾病中的效用。最近，患者血浆中的ctHPVDNA被发现是HPV OPSCC的一个有前景的生物标志物。该生物标志物的变化似乎与治疗反应相关，可能有助于识别分子残留疾病。根据PRISMA范围综述标准（从2017年至2024年7月），使用PubMed/MEDLINE、EMBASE和Cochrane图书馆数据库进行了文献综述。共纳入5篇文章和562名患者。三项研究探讨了ctHPVDNA清除在同步放化疗（CRT）中的作用，而其余两项研究将手术视为一种治疗选择。本范围综述的结果表明，ctHPVDNA在评估分子残留疾病方面有潜力作为一种有价值的生物标志物。需要进一步的研究来证实该标志物对这组患者进行分层的疗效。
